Stock analysts at Goldman Sachs dropped their price objective on shares of Groupon Inc (NASDAQ:GRPN) to $8.00 in a report issued on Wednesday, Stock Ratings Network.com reports. Goldman Sachs’ price objective would indicate a potential upside of 19.05% from the stock’s previous close. Groupon Inc (NASDAQ:GRPN) shares after opening at $6.02 moved to $6.03 on last trade day and at the end of the day closed at $5.33 . Company price to sales ratio in past twelve months was calculated as 1.41 and price to cash ratio as 2.93. Groupon Inc (NASDAQ:GRPN) showed a negative weekly performance of -23.75%.
Marissa Mayer, the CEO of Yahoo! Inc. (NASDAQ:YHOO) is poised to face a critical decision related to the initial public offering of Alibaba Group Holdings Limited as the search company plans to sell 208 million shares or 40% of its remaining stake in the Chinese e-commerce giant. Yahoo! Inc. (NASDAQ:YHOO) shares fell -6.63% in last trading session and ended the day on $34.07. YHOO return on equity ratio is recorded as 9.90% and its return on assets is 8.00%. Yahoo! Inc. (NASDAQ:YHOO) yearly performance is 30.69%.
Corinthian Colleges, Inc. (NASDAQ:COCO) reported financial results today for the third quarter ended March 31, 2014. The results for the quarter were below our previous third quarter guidance ranges for new student enrollment, revenue, and diluted earnings per share, owing primarily to weather-related school closures. (Guidance is for continuing operations only and excludes impairment, facility closing and severance charges and the deferred tax asset valuation allowance.) Corinthian Colleges Inc (NASDAQ:COCO) shares moved down -16.80% in last trading session and was closed at $0.899 while trading in range of $0.83 – $1.08 – Corinthian Colleges Inc (NASDAQ:COCO) year to date (YTD) performance is 49.52%.
Corcept Therapeutics Incorporated (NASDAQ:CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, reported its financial results for the quarter ended March 31, 2014. The company also reported that it is discontinuing its Phase 3 psychotic depression study (Study 14) based on the recommendation of the study’s data monitoring committee that the study was unlikely to meet its primary endpoint with statistical significance. Corcept Therapeutics Incorporated (NASDAQ:CORT) weekly performance is -54.98%. On last trading day company shares ended up $1.99. Corcept Therapeutics Incorporated (NASDAQ:CORT) distance from 50-day simple moving average (SMA50) is -49.36%. Analysts mean target price for the company is $3.50.
Novadaq® Technologies Inc. (NASDAQ:NVDQ) the leading developer and provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, today announced financial results for its first quarter ended March 31, 2014. Unless otherwise indicated, all dollar amounts in this press release are expressed in United States (U.S.) dollars. Novadaq Technologies Inc. (NASDAQ:NVDQ) shares after opening at $16.50 moved to $16.75 on last trade day and at the end of the day closed at $ 14.06. Company price to sales ratio in past twelve months was calculated as 22.04. Novadaq Technologies Inc. (NASDAQ:NVDQ) showed a negative weekly performance of -10.16%.